Conference Proceedings

Long-term safety and impact of natalizumab on disease activity and disability progression in patients with relapsing-remitting MS in clinical practice: TYSABRI (R) Observational Program (TOP)

H Wiendl, L Kappos, M Trojano, H Butzkueven, F Pellegrini, S Belachew, A Pace, D Desgrandchamps

JOURNAL OF NEUROLOGY | SPRINGER HEIDELBERG | Published : 2010